» Articles » PMID: 29904013

Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB P65, ERK1/2 and P38 Signaling Pathway

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Jun 16
PMID 29904013
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis.

Citing Articles

Nanocomposite Hydrogel for Real-Time Wound Status Monitoring and Comprehensive Treatment.

Lei H, Yu X, Fan D Adv Sci (Weinh). 2024; 11(42):e2405924.

PMID: 39269428 PMC: 11558094. DOI: 10.1002/advs.202405924.


Farrerol Alleviates Diabetic Cardiomyopathy by Regulating AMPK-Mediated Cardiac Lipid Metabolic Pathways in Type 2 Diabetic Rats.

Tu J, Liu Q, Sun H, Gan L Cell Biochem Biophys. 2024; 82(3):2427-2437.

PMID: 38878100 DOI: 10.1007/s12013-024-01353-2.


Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS-stimulated macrophages via inactivating MAPK signaling pathway.

Huang H, Tang S, Zhou Y, Cai Y Immun Inflamm Dis. 2024; 12(5):e1077.

PMID: 38722267 PMC: 11080961. DOI: 10.1002/iid3.1077.


The preventive effects of Lactobacillus casei 03 on Escherichia coli-induced mastitis in vitro and in vivo.

Li K, Yang M, Tian M, Jia L, Wu Y, Du J J Inflamm (Lond). 2024; 21(1):5.

PMID: 38395896 PMC: 10893599. DOI: 10.1186/s12950-024-00378-x.


Farrerol Alleviates Cerebral Ischemia-Reperfusion Injury by Promoting Neuronal Survival and Reducing Neuroinflammation.

Zhao R, Zhou X, Zhao Z, Liu W, Lv M, Zhang Z Mol Neurobiol. 2024; 61(9):7239-7255.

PMID: 38376762 DOI: 10.1007/s12035-024-04031-9.


References
1.
Yang W, Zerbe H, Petzl W, Brunner R, Gunther J, Draing C . Bovine TLR2 and TLR4 properly transduce signals from Staphylococcus aureus and E. coli, but S. aureus fails to both activate NF-kappaB in mammary epithelial cells and to quickly induce TNFalpha and interleukin-8 (CXCL8) expression in the udder. Mol Immunol. 2007; 45(5):1385-97. DOI: 10.1016/j.molimm.2007.09.004. View

2.
Zhang H, Yan J, Zhuang Y, Han G . Anti-inflammatory effects of farrerol on IL-1β-stimulated human osteoarthritis chondrocytes. Eur J Pharmacol. 2015; 764:443-447. DOI: 10.1016/j.ejphar.2015.07.012. View

3.
De Schepper S, De Ketelaere A, Bannerman D, Paape M, Peelman L, Burvenich C . The toll-like receptor-4 (TLR-4) pathway and its possible role in the pathogenesis of Escherichia coli mastitis in dairy cattle. Vet Res. 2007; 39(1):5. DOI: 10.1051/vetres:2007044. View

4.
Li D, Zhang N, Cao Y, Zhang W, Su G, Sun Y . Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-κB and MAPKs signal pathways. Eur J Pharmacol. 2013; 705(1-3):79-85. DOI: 10.1016/j.ejphar.2013.02.021. View

5.
Ghosh S, May M, Kopp E . NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998; 16:225-60. DOI: 10.1146/annurev.immunol.16.1.225. View